Habilitation

Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO

Retrieved on: 
Thursday, February 1, 2024
University, Research, Medical research, MD, Therapy, Gastroenterology, FDA, Habilitation, GPCR, Biotechnology, Drug discovery, Genentech, Drug development, Royal Free Hospital, Doctor of Philosophy, Medicine

Arndt has extensive experience in discovery, project and portfolio management, preclinical and clinical development, FDA negotiations and regulatory filings as well as business development.

Key Points: 
  • Arndt has extensive experience in discovery, project and portfolio management, preclinical and clinical development, FDA negotiations and regulatory filings as well as business development.
  • Eva-Lotta Allan, Chair of the Board of Directors commented: "It is with great pleasure that I, on behalf of the Board, welcome Arndt to Maxion.
  • Dr Arndt Schottelius, incoming CEO said: "Maxion's truly revolutionary technology has the unique opportunity to deliver first-in-class and best-in-class protein therapeutics to treat ion channel and GPCR-driven diseases.
  • I am delighted to join Maxion Therapeutics at such an exciting time in the Company's development.

Steven P. Rosenthal Gives a Second $1 Million to Support Innovation at Northeast Arc

Retrieved on: 
Tuesday, November 22, 2022
General Health, Fund Raising, Health, Foundation, Philanthropy, Trustee, Habilitation, Family support, Robert Rosenthal (businessman), Massachusetts Convention Center Authority, Multimedia, Liberty Tree Mall, Swedish National Board of Institutional Care, Ruderman Family Foundation, Black box theater, Acquisition, Disability, Rosenthal, Gold, State Employment Service (Azerbaijan), AIPAC, Transition, Loomis, City, Harvard College, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Heart, Risk, Boston University, Richard P. Rosenthal, Pharmaceutical industry, Management, Recreation

Boston businessman, Steven P. Rosenthal , Chairman of West Shore , has pledged $1 million to Northeast Arc in support of its Changing Lives Fund.

Key Points: 
  • Boston businessman, Steven P. Rosenthal , Chairman of West Shore , has pledged $1 million to Northeast Arc in support of its Changing Lives Fund.
  • Pictured from left: J.J.s father John Millard, J.J., his mother Joanna Millard, Rosenthal and Jo Ann Simons, President & CEO Northeast Arc.
  • He hopes the new gift will continue to encourage others to support Northeast Arc as well.
  • When Steve made his initial $1 million donation it was a real game-changer for us, said Jo Ann Simons , President and CEO of Northeast Arc.

HMNC Brain Health Appoints Dr. Bertram Müller-Myhsok as Head of Precision Psychiatry

Retrieved on: 
Thursday, February 24, 2022
University, GLOBE, Genetics, Department of Medicine – University of Pamplona, Faculty, Disorder, Head, MDD, LION, Statistical genetics, Bernhard Nocht Institute for Tropical Medicine, Tropical medicine, Habilitation, Max Planck Institute of Psychiatry, Industry, Company, Psychiatry, Ludwig Maximilian University of Munich, Lists of diseases, United Kingdom, Genetic testing, Technical University of Munich, Institute of technology, Human genetics, List of life sciences, Professor, Non-functional testing, VC, Senior, Artificial intelligence, Annemarie, Brain, TRD, Patient, Pontifical Xavierian University Faculty of Medicine, Knowledge, Research, Program, Department, Pharmaceutical industry, Medicine

MUNICH, Germany, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced today the appointment of Dr. Bertram Müller-Myhsok as its new Head of Precision Psychiatry, effective March 1, 2022. The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry in Munich has signed an additional contract with HMNC Brain Health next to his position at the Max-Planck-Institute. In his new role, Dr. Müller-Myhsok will help the Company to accelerate the development of differentiated treatment options through the combination of novel interventions with precision applications.

Key Points: 
  • MUNICH, Germany, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (HMNC'' or the Company), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced today the appointment of Dr. Bertram Mller-Myhsok as its new Head of Precision Psychiatry, effective March 1, 2022.
  • The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry in Munich has signed an additional contract with HMNC Brain Health next to his position at the Max-Planck-Institute.
  • As Head of Precision Psychiatry, Dr. Mller-Myhsoks decades of experience in human genetics research will allow HMNC Brain Health to advance its work utilizing genetic analyses and artificial intelligence to better detect the underlying genetic or physiological causes of disorders in specific individuals and develop personalized therapies for neuropsychiatric disorders.
  • HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission rates.